Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism

Summary

The primary aim of this study is to evaluate whether mid dose (safe dose) of Alteplase in addition to standard treatment with heparin (LMWH) in patients with pulmonary embolism (PE) at intermediate risk, it is effective to reduce: * right ventricular dysfunction * pulmonary hypertension 24 hours and 7 days after the treatment * PE recurrence to 7days and 30 days after the treatment without increasing the incidence of bleeding intra-extracranial

Timeline

Start

2016-03

Primary completion

2016-03

Completion

2016-03

Drugs

Indications